Kornimate/medical-research-clean huggingface dataset:
long-term assessment of remyelinating therapy

Conditions: Acute Optic Neuritis

Summary: the primary objective of the study is to assess full-field visual evoked potential (ff-vep) latency in subjects who were enrolled in study nct01721161 2 years (+ up to 12 months) after the last study visit. the secondary objective is to assess clinical progression and severity of central nervous system (cns) demyelinating disease in subjects who were enrolled in study nct01721161 2 years (+ up to 12 months) after the last study visit. intervention was administered in the previous study. the participants, investigator and outcome assessors remain blinded in this follow-up study.


Eligibility criteria:
key inclusion criteria: * must have participated in study nct01721161 and received at least 1 dose of biib033 or placebo, as per protocol, within 2 years (+ 4 months) from day 1 of this study (2 years from week 32 or projected week 32 visit, if the subject did not complete all visits in study nct01721161). key exclusion criteria: * not previously enrolled in study nct01721161 * subjects with recent kidney function, such as serum creatinine above upper limit of normal range, will not be allowed to receive administration of gd but will otherwise be allowed to participate in the study, including magnetic resonance imaging (mri) assessments not requiring the use of gd. * female subjects must have had a recent pregnancy test and must not be breastfeeding prior to mri assessments with gd. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: ff-vep mfvep human anti-lingo-1 biib033 aon
cardiovascular disease protection tissue

Conditions: Myocardial Ischemia

Summary: recent evidence of a potential role for cardiac progenitor cells (cpcs) in cardiac repair and the discovery of a vasoprotective axis of the renin-angiotensin system (ras) offer such breakthroughs. investigators have observed that an imbalance in the vasoprotective axis {angiotensin converting enzyme 2 (ace2)/angiotensin-(1-7) \[ang-(1-7)\]/mas receptor} and the vasodeleterious axis \[angiotensin converting enzyme (ace)/angiotensin ii (angii)/angii type 1 receptor (at1r)\] of the ras within the cpcs affects their functionality and regenerative potential. investigators believe that restoring the balance between these two axes of the ras is essential to improve cpc function and enhance their reparative capabilities. these observations have led to the hypothesis that genetic modification of cpcs by overexpression of ace2/ang-(1-7) will enhance their reparative function and improve their potential to attenuate myocardial ischemia-induced cardiac damage.

as a participant undergoes a clinically indicated heart transplant, or a left ventricular assist device (lvad) implantation, or a right heart biopsy, or atrial fibrillation surgery, or right atria cannulation, the following tissue samples will be collected: in the subjects undergoing orthotopic heart transplant (n=20), failed myocardial tissue samples will be collected from the diseased heart. for subjects undergoing left ventricular assist device implantation (n=60), small samples will be collected from the apex core (that would be routinely discarded at the time of the implantation procedure). for heart transplant subjects undergoing clinically indicated right heart biopsy (n=20), the collection of multiple samples including, excess myocardial biopsy samples that will not be utilized by pathology. for subjects undergoing any heart surgery (n=80), the collection of left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. in addition, a collection of 20ml (about one tablespoon) of blood will be taken from all subjects to analyze progenitor/inflammatory cells and inflammation cytokines and pertinent medical history.

Eligibility criteria:
inclusion criteria: * heart transplant surgery * left ventricular assist device implantation * heart surgery required for atrial fibrillation and right atria cannulation exclusion criteria: * we are collecting discarded tissues following surgery. there is no exclusion criteria for this study.
ptsd interview regarding future study design and equipment.

Conditions: Ptsd

Summary: to gain insight and perspective unique to individuals with a diagnosis of ptsd, this study will utilize an experiential one-to-one interview format. during the interview, an investigator will walk the participants through several aspects of an ans battery of tests, provide a tour and information about other equipment in the research lab and discuss tools and procedures associated with the application of chiropractic care. the aim of this research is to provide insight for future study designs that assess or provide care to individuals with ptsd.


Eligibility criteria:
inclusion criteria: * self-identify as having been diagnosed with ptsd. * between the ages 21-65 years old. exclusion criteria: -
kinetic of immune memory response after re-vaccination with meningococcal vaccine

Conditions: Meningococcal Disease; Meningococcal Meningitis

Summary: the purpose of this study is to determine when a memory immune response after re-vaccination with meningococcal c conjugate vaccine (menjugate) or challenge with meningococcal a/c polysaccharide vaccine can be observed, after initial vaccination with meningococcal c conjugate vaccine during the uk immunization campaign


Eligibility criteria:
inclusion criteria: * healthy adolescents between and including 13-15 years of age, who provide written informed consent and who received one immunization with chiron meningococcal c conjugate vaccine (menjugate) during the uk immunization campaign and for which documentation can be provided. exclusion criteria: * subjects with a previous or suspected disease caused by n. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); any serious acute, chronic or progressive disease
dart i - a phase iv study of 3 antiretroviral medicines in combination, in hiv patients who have not been previously treated with antiretroviral therapy

Conditions: HIV Infections; AIDS

Summary: the purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (efv), didanosine (ddi)-ec and lamivudine (3tc) leads to improved outcomes, as measured by viral load, cd4 counts, adherence, safety, and tolerability.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older infected with hiv and weigh at least 40 kg. * plasma hiv rna viral load of 1000 copies/ml or greater and cd4 count of 100 cells/ml or greater * be willing to use two forms of contraception throughout study * no previous exposure to antiretroviral (arv) drugs exclusion criteria: * pregnancy or breastfeeding * physical or psychiatric disability * proven or suspected acute hepatitis within 30 days prior to study entry * active aids-defining opportunistic infection or disease * history of acute or chronic pancreatitis

Keywords: hiv/aids
microneedles for diagnosis of ltbi

Conditions: Latent Tuberculosis

Summary: this study will evaluate new technique, microneedle, to detect latent tuberculosis (tb) in healthy volunteers

the cross-sectional study to investigate the effect of microneedle formulations and lengths of tuberculin ppd microneedles on the delayed-type hypersensitivity response in healthy volunteers.

Eligibility criteria:
inclusion criteria: 1. sex : male and female 2. age : 20-60 years 3. tb contacts or those at risk of tb e.g. health-care workers 4. hiv-negative healthy individuals exclusion criteria: 1. presence of an acute infection, as determined by investigators 2. receiving immunosuppression drugs e.g. steroids 3. having autoimmune diseases e.g. sle (systemic lupus erythematous) 4. being pregnant or breastfeeding
this study is a prospective, multi-center, real world, observational study, which aims at evaluating intermediate and long-term efficacy of endovascular treatment for tasc c&d aortoiliac occlusive disease.

Conditions: Peripheral Arterial Disease

Summary: this study is a prospective, multi-center, real world, observational study, which aims at evaluating the intermediate and long-term efficacy of endovascular treatment for tasc c\&d aortoiliac occlusive disease .it is estimated that 800 subjects diagnosed with tasc c\&d aortoiliac occlusive disease and receive endovascular treatments will be enrolled in nine centers from april 2021 to june 2027 nation-widely. all the subjects will be under follow-up for 60 months. there is no restriction on the endovascular techniques. the primary outcomes covers freedom from tlr at 60 months.

in the past decade, endovascular treatment has become the first-line treatment for iliac artery occlusion, while aorta - bilateral femoral artery bypass surgery is preferred for more complex iliac artery occlusion. however, recently, with advances in endovascular devices and techniques, endovascular interventions have gradually replaced open surgery in many clinical problems and have shown ideal safety and efficacy. currently, the optimal treatment for tasc, c\&d iliac artery occlusion is controversial, mostly based on limited data from single centers and few large multicenter databases or registries. in addition, the long-term efficacy of stents implantation in iliac artery disease remind unknown and might be influenced by stent type and calcification. therefore, the purpose of this study was to evaluate the long-term efficacy and safety of endovascular treatment for tasc, c\&d iliac artery occlusion in a multicenter study.

Eligibility criteria:
inclusion criteria: 1. rutherford grades 3-6. 2. follow the follow-up arrangement. 3. age: 18-80 years old. 4. the target lesions were in the lower abdominal aorta and/or the common iliac artery and/or the external iliac artery. 5. the stenosis degree ≥50%, or restenosis (received pta or other adjuvant therapy, including bare or covers stents), or complete occlusion, or the presence of aortailiac artery thrombosis after pmt or cdt thrombus clearance, and then further endovascular therapy perfomred. 6. signed informed consent. exclusion criteria: 1. known allergy to drugs used in this study, including antiplatelet or anticoagulant drugs, etc. 2. allergy to iodine contrast agent allergy; 3. coagulation dysfunction or hypercoagulability; 4. breast-feeding or pregnant women; 5. life expectancy \< 24 months; 6. body condition can not tolerate endovascular treatment; 7. type 2b, type 3 lower limb ischemia patients

Keywords: aortoiliac occlusive disease
research on the diagnostic value of machine learning model based on clinical data in patients with coronary heart disease

Conditions: Coronary Heart Disease; Acute Myocardial Infarction; Angina

Summary: based on the clinical data of patients, a machine learning model for coronary heart disease diagnosis was established to evaluate whether the model could improve the accuracy of coronary heart disease diagnosis, and to evaluate its authenticity, reliability and benefits.

a total of 300 patients with chd who were hospitalized in the first affiliated hospital of xinjiang medical university from august 2021 to february 2022 were selected, all of whom met the diagnostic criteria of chd formulated by the world health organization (who) and excluded diseases such as highly severe valvular disease and congenital heart disease.a total of 300 healthy subjects from the first affiliated hospital of xinjiang medical university during the same period were selected as controls.observation indicators included: clinical indicators collected included: general conditions: gender, age, medical history;blood biochemical indexes, such as blood routine, liver function, kidney function, blood lipid, blood glucose, myocardial markers, electrolyte, serum creatinine concentration, body mass index, bnp and other indicators;related tests such as electrocardiogram, holter electrocardiogram, cardiac ultrasound (left atrial diameter, ascending aorta, ventricular septal thickness, left posterior wall thickness, right ventricular diameter, ejection fraction, abnormal ventricular wall motion, evidence of infarction or ischemia, valve abnormality, congenital heart disease, etc.);signs include: audio data of heart sounds in nine parts of precardiac area;medication status.all blood biochemical indexes and examinations were completed in the laboratory department and ultrasound department of our hospital, and the physical signs were completed in the ward.the results of coronary angiography, pre-hospital and post-hospital echocardiography and other related data were recorded.machine learning model was constructed based on clinical data to assist diagnosis of patients with coronary heart disease

Eligibility criteria:
inclusion criteria: * patients who meet the diagnostic criteria for chd set by the world health organization exclusion criteria: * exclude serious valvular disease, congenital heart disease, respiratory system and other diseases.

Keywords: machine learning deep learning electronic patient record auscultation artificial intelligence
efficacy of azithromycin prophylaxis in preventing recurrent acute sinusitis in children

Conditions: Sinusitis

Summary: the purpose of this study is to evaluate efficacy of azithromycin prophylaxis in preventing recurrent acute sinusitis in children.

a prospective, randomized, double-blind, placebo controlled trial of azithromycin in preventing recurrent acute sinusitis in children

Eligibility criteria:
inclusion criteria: * children between the age of 5 years and 15 years with the diagnosis of recurrent acute sinusitis who are attending the outpatient pediatric department, pediatric allergy clinic, and the ear, nose, throat clinic. exclusion criteria: * patients who have allergic rhinitis, chronic sinusitis, a history of allergic reactions to azithromycin or macrolides, treatments with immunotherapy or ivig or gentamycin solution or pneumococcal vaccine during study period.

Keywords: sinusitis azithromycin
effect of lower extremity joint manipulation on a lower extremity somatosensory illusion

Conditions: Coordination and Balance Disturbances; Healthy

Summary: the purpose of this study is to examine the influence of extremity manipulation on individual's center of pressure after they adapt to an ankle based illusion.


Eligibility criteria:
inclusion criteria: * no previous surgeries * not knowingly pregnant * no neuromusculoskeletal injuries or systemic diseases that could affect an individual's ability to stand on an incline for 3 minutes with their eyes closed. exclusion criteria: - weight over the force plate operating limit of 440 lbs
relationship between arterial variations and patency of arteriovenous fistulae

Conditions: Arteriovenous Fistula; Ultrasound; Artery

Summary: in 2019, kdoqi considered that uremic patients with a life expectancy of more than one year should require hemodialysis as an effective renal replacement therapy before preparation of kidney transplantation. arteriovenous fistula, as the lifeline of uremic patients, plays an important role in their daily hemodialysis. the patency of arteriovenous fistula is largely restricted by the inflow artery. according to available medical literatures, an incidence rate of variations in the branching pattern of the main arteries in the upper limb is ranged from 7.2% to 25.0%. and there is a large difference in the incidence rate between sex and race, furthermore, the incidence rate of variations in the branching pattern of the main arteries in the upper limb of chinese is still unclear. the brachial artery is the main artery of the upper limb. it gives off two terminal branches at the distal end of the elbow crease, the radial and ulnar arteries, the former one often serves as an arterial inflow to create an arteriovenous fistula in the forearm. high bifurcation of the brachial artery (hbba) seems to be a common variation which may result in immaturity or disfunction of arteriovenous fistulas. therefore, the purpose of this study is to investigate the variations in the branching pattern of the main arteries in the upper limb of chinese, in order to study on the hemodynamic changes, and their influence on the establishment, maturation and failure of arteriovenous fistulas in the upper limb.

this is a prospective analysis research, collecting information after patients admission, including basic information, primary disease status, dialysis intubation status, current dialysis access status, last dialysis access maintenance status and other relevant data. the above-mentioned information data is collected when the patient is admitted into the department of vascular surgery, and is recorded in the "information collection, diagnosis and treatment process of hemodialysis patients in the department of vascular surgery" form for retention and filing. during the study period, all patients who were admitted to the vascular surgical department and signed the "informed consent" before the upper extremity artery screening according to the corresponding procedures.

Eligibility criteria:
inclusion criteria: * patients of vascular surgical inpatient department * patients will sign the "informed consent" and be able to receive related ultrasound examinations exclusion criteria: * patients of other surgical inpatient department
cyberknife radiosurgery for locally advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy with radiosurgery for locally advanced pancreas cancer.

the purpose of the trial is to test the efficacy of treating locally advanced pancreatic cancer with 5fu and concurrent conventional radiotherapy followed by precisely administered single fraction of high-energy radiation using a radiosurgical technique.

Eligibility criteria:
inclusion criteria:- pancreatic tumors not to exceed 7.5 cm. * histologically confirmed malignancies of the pancreas, (ampulla of vater or periampullary duodenum, tumors may be included when the head of pancreas is secondarily involved and unresectable criteria are met). * unresectable by ct criteria or unresectable at exploratory laparotomy or laparoscopy. ct criteria for unresectability include encasement of the superior mesenteric vein (smv), portal vein (pv) or invasion of the celiac artery or superior mesenteric artery (sma). * patients with metastatic disease may be treated if they are symptomatic from the primary tumor. * eastern clinical oncology group performance status 0, 1 or 2. exclusion criteria:chemotherapy within 1 month of registration.
patterned experience for preterm infants

Conditions: Complication of Prematurity

Summary: the pepi study is designed to provide a patterned feeding experience. by using a regularly occurring and necessary caregiving event, feeding, as the vehicle for the patterned experience, the intervention should be effective at promoting and reinforcing neuronal growth and connections that are critical for neurobehavioral and cognitive function while at the same time being cost effective in its delivery.

infants will be randomly assigned to a study group or control group. the research study will last for approximately twenty four months. infants will have daily assessments while in the hospital and three study visits after hospital discharge. all post-discharge visits will occur in an out patient hospital setting. during the first days of life, study staff will start observing infant's development by using assessment tools. lab samples include one blood sample taken when other blood is being collected in the first days of life and one saliva sample when the infants starts bottle feeding. when tube feedings are started in the study group, caregivers (nurses, parents or research staff) will gently place hands on the infant while in the incubator (ill babies) or bundled outside the incubator. if the infant is in the control group, they will receive standard tube feeding care. when oral feedings are started in the study group, the infant will have an opportunity at every feeding to be breast or bottle fed while being held. if unable to complete the entire feeding orally, the rest will be tube fed. if the infant is in the control group, feeding opportunities will be decided by the medical team providing care. all infants will be observed during oral feedings twice a week while in the hospital. study staff will watch heart rate, sucking activity (a sensor on the chin) and level of wakefulness.

Eligibility criteria:
inclusion criteria: * infants born ≤ 32 weeks gestation exclusion criteria: * infants will be excluded if the infant has gastrointestinal, craniofacial, cardiovascular, neuromuscular, and/or genetic defects

Keywords: preterm infant neurobehavioral development
safety and efficacy of sugammadex (org 25969, mk-8616) in participants with or having a past history of pulmonary disease (19.4.308) (p05932) (mk-8616-017)

Conditions: Anesthesia, General

Summary: the purpose of the trial is to research the safety and to show faster recovery after administration of 2.0 mg/kg or 4.0 mg/kg sugammadex (org 25969, mk-8616) given as a reversal agent for 0.6 mg/kg (0.15 mg/kg maintenance dose) rocuronium (zemuron®) in participants diagnosed with or having a history of pulmonary disease. all drug administration will be via the intravenous (iv) route.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) class 1 to 3; * has been diagnosed with or having a past history of pulmonary disease; * is scheduled for elective surgical procedure under general anesthesia requiring neuromuscular block with the use of rocuronium; * is scheduled for surgery in supine position; * has given written informed consent; exclusion criteria: * is expected to have a difficult intubation due to anatomical malformations; * has known or suspected of having neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction; * has known or suspected of having a (family) history of malignant hyperthermia; * has known or suspected of having an allergy to narcotics, muscle relaxants or other medications used during surgery; * is receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and mg2+; * is a female who is pregnant or breast-feeding; * is a female of childbearing potential not using an acceptable method of birth control \[condom or diaphragm with spermicide, vasectomized partner (\> 6 months), iud, abstinence\] or using only hormonal contraception as birth control; * has already participated in a sugammadex trial including protocol 19.4.308; * has participated in another clinical trial, not pre-approved by organon, within 30 days of entering into protocol 19.4.308.
clinical performance of the maternit21 plus ldt in multiple gestation pregnancies

Conditions: Down Syndrome; Edwards Syndrome; Patau Syndrome; Turner Syndrome

Summary: this study will evaluate the clinical performance of massively parallel sequencing (mps) using the maternit21 plus ldt in the detection of fetal aneuploidy in circulating cfdna extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk for fetal aneuploidy.


Eligibility criteria:
inclusion criteria: * subject was pregnant with a multiple gestation and received nipt with the maternit21 plus ldt and a valid test result is available; * subject was 18 years of age or older at the time of nipt; * subject provides signed and dated informed consent in english; exclusion criteria: * subjects' treating physician is not located in the united states.

Keywords: noninvasive prenatal testing